Cell adhesion molecules and inflammation in acute coronary syndromes: markers and emerging risk factors.

and organization of the metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-CHF). Lancet 1999; 353: 2001–7. [8] Bigger JT Jr, for the Coronary Artery bypass graft (CABG) Patch trial investigators. Propylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass surgery. N Engl J Med 1997; 337: 1569–75. [9] Moss AJ, Hall WJ, Cannom DS et al. for the MADIT Investigators. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996; 335: 1933–40. [10] Buxton AE, Lee KL, Fisher JD et al. for the MUSTT Investigators. A randomised study for the prevention of sudden death in patients with coronary artery disease. N Engl J Med 1999; 341: 1882–90. [11] Every NR, Hlatky MA, McDonald KM, Weaver MD, Hallstom AP. Estimating the proportion of post-myocardial infarction patients who may benefit form implantable defibrillator placement from analysis of the CAST registry. Am J Cardiol 1998; 82: 683–5. [12] Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–9.